{"name": "Oxyrane UK",
 "permalink": "oxyrane-uk",
 "crunchbase_url": "http://www.crunchbase.com/company/oxyrane-uk",
 "homepage_url": "http://www.oxyrane.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@oxyrane.com",
 "phone_number": "+44 (0) 161 227 8887",
 "description": "",
 "created_at": "Fri Nov 18 04:25:36 UTC 2011",
 "updated_at": "Fri Nov 18 04:25:35 UTC 2011",
 "overview": "\u003Cp\u003EOxyrane UK Limited is a biopharmaceutical company dedicated to the development of novel and biosuperior enzyme replacement therapies (ERT) to treat lysosomal storage diseases, a class of more than 40 rare, inherited diseases. Founded in 2006, the Company is headquartered in Manchester, United Kingdom with research facilities in Ghent, Belgium. \u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       38],
      "assets/images/resized/0016/2877/162877v1-max-150x150.jpg"],
     [[250,
       64],
      "assets/images/resized/0016/2877/162877v1-max-250x250.jpg"],
     [[257,
       66],
      "assets/images/resized/0016/2877/162877v1-max-450x450.jpg"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$26.5M",
 "funding_rounds":
  [{"round_code": "d",
    "source_url": "http://www.finsmes.com/2011/11/oxyrane-raises-26-5m-series-funding.html?utm_source=feedburner\u0026utm_medium=feed\u0026utm_campaign=Feed%3A+finsmes%2FcNHu+%28FinSMEs%29",
    "source_description": "Oxyrane Raises $26.5M in Series D Funding",
    "raised_amount": 26500000.0,
    "raised_currency_code": "USD",
    "funded_year": 2011,
    "funded_month": 11,
    "funded_day": 17,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Forbion Capital Partners",
         "permalink": "forbion-capital-partners",
         "image":
          {"available_sizes":
            [[[150,
               60],
              "assets/images/resized/0010/0907/100907v1-max-150x150.png"],
             [[200,
               80],
              "assets/images/resized/0010/0907/100907v1-max-250x250.png"],
             [[200,
               80],
              "assets/images/resized/0010/0907/100907v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Morningside Group",
         "permalink": "morningside-group",
         "image":
          {"available_sizes":
            [[[150,
               25],
              "assets/images/resized/0002/9760/29760v1-max-150x150.png"],
             [[238,
               41],
              "assets/images/resized/0002/9760/29760v1-max-250x250.png"],
             [[238,
               41],
              "assets/images/resized/0002/9760/29760v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "New Science Ventures",
         "permalink": "new-science-ventures",
         "image":
          {"available_sizes":
            [[[150,
               88],
              "assets/images/resized/0004/2733/42733v2-max-150x150.png"],
             [[158,
               93],
              "assets/images/resized/0004/2733/42733v2-max-250x250.png"],
             [[158,
               93],
              "assets/images/resized/0004/2733/42733v2-max-450x450.png"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}